FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
0001390478 false 0001390478 2022-11-14 2022-11-14 iso4217:USD xbrli:shares...
Maxim Group analyst Jason McCarthy reiterated a Buy rating on SELLAS Life Sciences Group (SLS - Research Report) yesterday and set a price target...
Shares of SELLAS Life Sciences Group (NASDAQ: SLS) were in a downward spiral on Monday morning as the late-stage clinical biopharmaceutical...
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast Today...
– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan:...
0001390478December 312022Q3FALSE00013904782022-01-012022-09-3000013904782022-11-10xbrli:shares00013904782022-09...
E ratio of -2.14.https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-sellas-life-sciences-group-sls?utm_source=advfn.com...
- Median Overall Survival for GPS Combination (GPS in Combination with Keytruda) was 18.4 Months Compared to...
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the...
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the...
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the...
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the...
GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect -GFH009 at pH 6.0 Decreased...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.